Jeff Tyner group
(left to right): Nicola Long, Jeffrey Tyner, Ph.D., Kara Johnson, and Cristina Tognon, Ph.D. co-authored new research published in Cancer Cell. Their findings are the latest from the OHSU Knight Cancer Institutes Beat AML platform for analyzing the cancer cell gene expression, drug sensitivities, and medical outcomes of more than 800 people with acute myeloid leukemia. (OHSU/Christine Torres Hicks)
Jeff Tyner, Ph.D.
Jeffrey Tyner, Ph.D., co-led new research that zeros in on a potential drug target to stop acute myeloid leukemia. (OHSU/Christine Torres Hicks)
Shannon McWeeney, Ph.D.
Shannon McWeeney, Ph.D., professor and head of the Division of Bioinformatics and Computational Biology and an OHU Knight Cancer Institute researcher, Sept. 12, 2018. (OHSU/Kristyna Wentz-Graff)
Jeff Tyner, Ph.D.
Jeffrey Tyner, Ph.D., professor of cell, developmental and cancer biology in the OHSU School of Medicine. (OHSU/Christine Torres Hicks)
Kyle Ellrott, Ph.D. (OHSU)
David Dorr, M.D., M.S. (OHSU)
OHSU experts tapped for national Artificial Intelligence initiative
David Dorr, M.D., M.S., left, chief research information officer and professor of medical informatics and clinical epidemiology in the OHSU School of Medicine, Kyle Ellrott, Ph.D., center, assistant professor of biomedical engineering in the OHSU School of Medicine, is part of the Bridge Center, and Shannon McWeeney, Ph.D., right, chief data officer for the OHSU Knight Cancer Institute. (OHSU)
Pepper Schedin, Ph.D. (OHSU)